The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.
E
E
Matutes
A G
AG
Bosanquet
R
R
Wade
S M
SM
Richards
M
M
Else
D
D
Catovsky
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001681:Biological Assay; D016903:Drug Monitoring; D019008:Drug Resistance, Neoplasm; D005500:Follow-Up Studies; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy / Q000401:mortality; D018579:Patient Selection; D011237:Predictive Value of Tests; D011379:Prognosis; D011897:Random Allocation; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000494:pharmacology
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine